Genentech Partners with Xenon to Discover, Develop Genetically Targeted Pain Drugs, Companion Tests
January 11, 2012
Genentech Partners with Xenon to Discover, Develop Genetically Targeted Pain Drugs, Companion Tests
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Xenon and Genentech Ink Rx, Companion Dx Collaboration and License Pact
January 11, 2012 / GenomeWeb Daily News - Researchers Develop Investigational MDx to ID Glioblastoma Patients who Derive Benefit from Avastin
June 5, 2013 / Pharmacogenomics Reporter - Roche Receives FDA Nod for New PGx Indication for Tarceva in Metastatic NSCLC with Companion Dx
May 15, 2013 / Pharmacogenomics Reporter - FDA Approves Roche Test as CDx for Tarceva for Treating Certain NSCLC Patients
May 15, 2013 / GenomeWeb Daily News - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter